Tests proton radiotherapy with two immunotherapy drugs for liver cancer

Trial details

Who runs it

Chang Gung Memorial Hospital

Trial code

NCT06999694

Record updated

1 October 2026

Original description

Tremelimumab plus durvalumab (STRIDE regimen) is an approved first-line therapy for unresectable hepatocellular carcinoma (HCC), yet it shows limited efficacy with an ORR of only 20.1%. Proton radiotherapy (RT), known for its precision and tissue-sparing advantages, has demonstrated improved survival outcomes and reduced toxicity compared to X-ray RT. Retrospective data suggest that combining proton RT with immune checkpoint inhibitors yields a promising ORR of 61.5%. Preclinical studies further support enhanced antitumor immunity when RT is combined with PD-L1 and CTLA-4 blockade. This phase II, single-arm clinical trial aims to evaluate the safety, efficacy, and immunologic effects of combining proton RT with tremelimumab and durvalumab in patients with unresectable HCC.Read full original descriptionShow less

Proton Radiotherapy Combined With Tremelimumab and Durvalumab for BCLC Stage B and C Hepatocellular Carcinoma

Tremelimumab plus durvalumab (STRIDE regimen) is an approved first-line therapy for unresectable hepatocellular carcinoma (HCC), yet it shows limited efficacy with an ORR of only 20.1%. Proton radiotherapy (RT), known for its precision and tissue-sparing advantages, has demonstrated improved survival outcomes and reduced toxicity compared to X-ray RT. Retrospective data suggest that combining proton RT with immune checkpoint inhibitors yields a promising ORR of 61.5%. Preclinical studies further support enhanced antitumor immunity when RT is combined with PD-L1 and CTLA-4 blockade. This phase II, single-arm clinical trial aims to evaluate the safety, efficacy, and immunologic effects of combining proton RT with tremelimumab and durvalumab in patients with unresectable HCC.

Inclusion: Participants must have diagnosis of HCC that is deemed unsuitable for surgical resection or transplant. Participants may have multiple lesions with a total maximal tumor dimension of < 20 cm, and no one lesion > 15 cm. Diagnosis should be confirmed by at least 1 criterion listed below:; Histologically or cytologically proven diagnosis of HCC; Typical arterial enhancement and delayed washout on multiphasic CT or MRI; Age ≥18 years at the time of signing informed consent document; ECOG performance status 0-1; Barcelona Clinic Liver Cancer (BCLC) stages Intermediate (B) or Advanced (C); Child-Pugh score 5-6 liver function within 28 days of study registration; Documented virology status of hepatitis B virus (HBV), as confirmed by screening HBV serology test; Documented virology status of hepatitis C virus (HCV), as confirmed by screening HCV serology test; Ability to understand and the willingness to sign a written informed consent document; Adequate bone marrow, liver, and renal function within 4 weeks before study registration; Hemoglobin ≥ 9.0 g/dL; Absolute neutrophil count (ANC) ≥ 1,000/mm3; Platelet count ≥ 50,000/μL; Total bilirubin < 2.5 mg/dL; Serum albumin >2.8 g/dL; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × upper limit of normal (ULN); Prothrombin time ≤ 6 seconds prolonged; Serum creatinine ≤ 1.5 mg/dL.

Exclusion: Prior radiotherapy to the region of the liver that would result in overlap of radiation therapy fields; Prior selective internal radiotherapy/hepatic arterial yttrium therapy, at any time; Presence of distant metastases that cannot be encompassed by proton radiotherapy; Severe, active co-morbidity, defined as follows:; Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months prior to registration; Myocardial infarction within the last 6 months prior to study entry; Acute bacterial or fungal infection requiring intravenous antibiotics within 28 days prior to study entry; A bleeding episode within 6 months prior to study entry due to any cause; Thrombolytic therapy within 28 days prior to study entry; Known bleeding or clotting disorder; Uncontrolled psychotic disorder; Prior solid organ transplantation; Prior or active autoimmune disease (AID) including autoimmune hepatitis, inflammatory bowel disease, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjogren's syndrome, Guillain-Barre syndrome, and multiple sclerosis; Prior or active thrombotic or bleeding disorders, hemoptysis, cerebral vascular accident, significant cardiac disease (ischemic or congestive heart failure), or gastrointestinal perforation; Prior invasive malignancy unless disease free for a minimum of 2 years; Untreated active hepatitis B or hepatitis C; Inability to treat all sites of disease by proton radiotherapy (such as extrahepatic metastases or massive liver tumors whereby the liver constraints cannot be met for covering all sites of liver tumors using proton radiotherapy.); Known HIV infection; Moderate to severe or intractable ascites; Untreated or incomplete treated esophageal or gastric varices; Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception.

ClinicalTrials.gov NCT06999694